Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.
BIOLASE Inc. (NASDAQ: BIOL) shares spiked 13.91 percent to close at $2.62 a share Thursday. The stock traded between $2.34 and $2.85 on volume of 799,558 shares traded. The company has stated that it expects net revenues for the fourth quarter of 2013 to be approximately $15.25 million. Shares of BIOLASE are down approximately 7.0 percent year-to-date.
Get more information on BIOLASE and free access to the in-depth equity report at:
www.FiveStarEquities.com/BIOL
OraSure Technologies, Inc. (NASDAQ: OSUR) shares jumped 10.27 percent to close at $6.12 a share Wednesday. The stock traded between $6.00 and $6.38 on volume of 1.53 million shares traded. The company reported revenues were $28.8 million for the fourth quarter of 2013, an increase of 30.0 percent when compared to a year ago. Shares of OraSure Technologies have are down approximately 3.0 percent year-to-date.
Get more information on OraSure Technologies free access to the in-depth equity report at:
www.FiveStarEquities.com/OSUR
Prima Biomed Ltd. (NASDAQ: PBMD) shares soared 45.30 percent to close at $1.70 a share Thursday. The stock traded between $1.25 and $1.95 on volume 3.68 million shares traded. The company announced that its amended CAN-004 protocol has been approved in multiple jurisdictions, such as Latvia, Lithuania, Bulgaria, Ukraine and Belarus. Shares of Prima Biomed are up approximately 55.0 percent in the past year.
Get more information on Prima Biomed and free access to the in-depth equity report at:
www.FiveStarEquities.com/PBMD
Repros Therapeutics Inc. (NASDAQ: RPRX) shares surged 15.77 percent to close at $17.91 a share Thursday. The stock traded between $16.64 and $19.09 on volume of 1.73 million shares traded. The company is on pace to submit a New Drug Application for Androxal before the end of 2014. Shares of Repros Therapeutics are down approximately 2.0 percent year-to-date.
Get more information on Repros Therapeutics and free access to the in-depth equity report at:
www.FiveStarEquities.com/RPRX
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Contact:
Five Star Equities
[email protected]